1 November 2019 in Cell Reports
Impaired mitochondrial respiratory activity contributes to the development of insulin resistance in type 2 diabetes. Metformin, a first-line antidiabetic drug, functions mainly by improving patients' hyperglycemia and insulin resistance. However, its mechanism of action is still not well understood. We show here that pharmacological metformin concentration increases mitochondrial respiration, membrane potential, and ATP levels in hepatocytes and a clinically relevant metformin dose increases liver mitochondrial density and complex 1 activity along with improved hyperglycemia in high-fat- diet (HFD)-fed mice. Metformin, functioning through 5' AMP-activated protein kinase (AMPK), promotes mitochondrial fission to improve mitochondrial respiration and restore the mitochondrial life cycle. Furthermore, HFD-fed-mice with liver-specific knockout of AMPKα1/2 subunits exhibit higher blood glucose levels when treated with metformin. Our results demonstrate that activation of AMPK by metformin improves mitochondrial respiration and hyperglycemia in obesity. We also found that supra-pharmacological metformin concentrations reduce adenine nucleotides, resulting in the halt of mitochondrial respiration. These findings suggest a mechanism for metformin's anti-tumor effects.
21 July 2006 in Circulation Research
Mitochondrial Ca 2+ ([Ca 2+ ] m ) regulates oxidative phosphorylation and thus contributes to energy supply and demand matching in cardiac myocytes. Mitochondria take up Ca 2+ via the Ca 2+ uniporter (MCU) and extrude it through the mitochondrial Na + /Ca 2+ exchanger (mNCE). It is controversial whether mitochondria take up Ca 2+ rapidly, on a beat-to-beat basis, or slowly, by temporally integrating cytosolic Ca 2+ ([Ca 2+ ] c ) transients. Furthermore, although mitochondrial Ca 2+ efflux is governed by mNCE, it is unknown whether elevated intracellular Na + ([Na + ] i ) affects mitochondrial Ca 2+ uptake and bioenergetics. To monitor [Ca 2+ ] m , mitochondria of guinea pig cardiac myocytes were loaded with rhod-2–acetoxymethyl ester (rhod-2 AM), and [Ca 2+ ] c was monitored with indo-1 after dialyzing rhod-2 out of the cytoplasm. [Ca 2+ ] c transients, elicited by voltage-clamp depolarizations, were accompanied by fast [Ca 2+ ] m transients, whose amplitude (Δ) correlated linearly with Δ[Ca 2+ ] c . Under β-adrenergic stimulation, [Ca 2+ ] m decay was ≈2.5-fold slower than that of [Ca 2+ ] c , leading to diastolic accumulation of [Ca 2+ ] m when amplitude or frequency of Δ[Ca 2+ ] c increased. The MCU blocker Ru360 reduced Δ[Ca 2+ ] m and increased Δ[Ca 2+ ] c , whereas the mNCE inhibitor CGP-37157 potentiated diastolic [Ca 2+ ] m accumulation. Elevating [Na + ] i from 5 to 15 mmol/L accelerated mitochondrial Ca 2+ decay, thus decreasing systolic and diastolic [Ca 2+ ] m . In response to gradual or abrupt changes of workload, reduced nicotinamide-adenine dinucleotide (NADH) levels were maintained at 5 mmol/L [Na + ] i , but at 15 mmol/L, the NADH pool was partially oxidized. The results indicate that (1) mitochondria take up Ca 2+ rapidly and contribute to fast buffering during a [Ca 2+ ] c transient; and (2) elevated [Na + ] i impairs mitochondrial Ca 2+ uptake, with consequent effects on energy supply and demand matching. The latter effect may have implications for cardiac diseases with elevated [Na + ] i .
13 April 2010 in Circulation
Background—
Oxidative stress is causally linked to the progression of heart failure, and mitochondria are critical sources of reactive oxygen species in failing myocardium. We previously observed that in heart failure, elevated cytosolic Na + ([Na + ] i ) reduces mitochondrial Ca 2+ ([Ca 2+ ] m ) by accelerating Ca 2+ efflux via the mitochondrial Na + /Ca 2+ exchanger. Because the regeneration of antioxidative enzymes requires NADPH, which is indirectly regenerated by the Krebs cycle, and Krebs cycle dehydrogenases are activated by [Ca 2+ ] m , we speculated that in failing myocytes, elevated [Na + ] i promotes oxidative stress.
Methods and Results—
We used a patch-clamp–based approach to simultaneously monitor cytosolic and mitochondrial Ca 2+ and, alternatively, mitochondrial H 2 O 2 together with NAD(P)H in guinea pig cardiac myocytes. Cells were depolarized in a voltage-clamp mode (3 Hz), and a transition of workload was induced by β-adrenergic stimulation. During this transition, NAD(P)H initially oxidized but recovered when [Ca 2+ ] m increased. The transient oxidation of NAD(P)H was closely associated with an increase in mitochondrial H 2 O 2 formation. This reactive oxygen species formation was potentiated when mitochondrial Ca 2+ uptake was blocked (by Ru360) or Ca 2+ efflux was accelerated (by elevation of [Na + ] i ). In failing myocytes, H 2 O 2 formation was increased, which was prevented by reducing mitochondrial Ca 2+ efflux via the mitochondrial Na + /Ca 2+ exchanger.
Conclusions—
Besides matching energy supply and demand, mitochondrial Ca 2+ uptake critically regulates mitochondrial reactive oxygen species production. In heart failure, elevated [Na + ] i promotes reactive oxygen species formation by reducing mitochondrial Ca 2+ uptake. This novel mechanism, by which defects in ion homeostasis induce oxidative stress, represents a potential drug target to reduce reactive oxygen species production in the failing heart.
1 August 2008 in Circulation Research
Mitochondrial ATP production is continually adjusted to energy demand through coordinated increases in oxidative phosphorylation and NADH production mediated by mitochondrial Ca 2+ ([Ca 2+ ] m ). Elevated cytosolic Na + impairs [Ca 2+ ] m accumulation during rapid pacing of myocytes, resulting in a decrease in NADH/NAD + redox potential. Here, we determined 1) if accentuating [Ca 2+ ] m accumulation prevents the impaired NADH response at high [Na + ] i ; 2) if [Ca 2+ ] m handling and NADH/NAD + balance during stimulation is impaired with heart failure (induced by aortic constriction); and 3) if inhibiting [Ca 2+ ] m efflux improves NADH/NAD + balance in heart failure. [Ca 2+ ] m and NADH were recorded in cells at rest and during voltage clamp stimulation (4Hz) with either 5 or 15 mmol/L [Na + ] i . Fast [Ca 2+ ] m transients and a rise in diastolic [Ca 2+ ] m were observed during electric stimulation. [Ca 2+ ] m accumulation was [Na + ] i -dependent; less [Ca 2+ ] m accumulated in cells with 15 Na + versus 5 mmol/L Na + and NADH oxidation was evident at 15 mmol/L Na + , but not at 5 mmol/L Na + . Treatment with either the mitochondrial Na + /Ca 2+ exchange inhibitor CGP-37157 (1 μmol/L) or raising cytosolic P i (2 mmol/L) enhanced [Ca 2+ ] m accumulation and prevented the NADH oxidation at 15 mmol/L [Na + ] i . In heart failure myocytes, resting [Na + ] i increased from 5.2±1.4 to 16.8±3.1mmol/L and net NADH oxidation was observed during pacing, whereas NADH was well matched in controls. Treatment with CGP-37157 or lowering [Na + ] i prevented the impaired NADH response in heart failure. We conclude that high [Na + ] i (at levels observed in heart failure) has detrimental effects on mitochondrial bioenergetics, and this impairment can be prevented by inhibiting the mitochondrial Na + /Ca 2+ exchanger.
22 January 2014 in Proceedings of the National Academy of Sciences
Chronic neurohormonal and mechanical stresses are central features of heart disease. Increasing evidence supports a role for the transient receptor potential canonical channels TRPC3 and TRPC6 in this pathophysiology. Channel expression for both is normally very low but is increased by cardiac disease, and genetic gain- or loss-of-function studies support contributions to hypertrophy and dysfunction. Selective small-molecule inhibitors remain scarce, and none target both channels, which may be useful given the high homology among them and evidence of redundant signaling. Here we tested selective TRPC3/6 antagonists (GSK2332255B and GSK2833503A; IC50, 3–21 nM against TRPC3 and TRPC6) and found dose-dependent blockade of cell hypertrophy signaling triggered by angiotensin II or endothelin-1 in HEK293T cells as well as in neonatal and adult cardiac myocytes. In vivo efficacy in mice and rats was greatly limited by rapid metabolism and high protein binding, although antifibrotic effects with pressure overload were observed. Intriguingly, although gene deletion of TRPC3 or TRPC6 alone did not protect against hypertrophy or dysfunction from pressure overload, combined deletion was protective, supporting the value of dual inhibition. Further development of this pharmaceutical class may yield a useful therapeutic agent for heart disease management. Significance Cardiac hypertrophy and dysfunction in response to sustained hormonal and mechanical stress are sentinel features of most forms of heart disease. Activation of non–voltage-gated transient receptor potential canonical channels TRPC3 and TRPC6 may contribute to this pathophysiology and provide a therapeutic target. Effects from combined selective inhibition have not been tested previously. Here we report the capability of highly selective TRPC3/6 inhibitors to block pathological hypertrophic signaling in several cell types, including adult cardiac myocytes. We show in vivo redundancy of each channel; individual gene deletion was not protective against sustained pressure overload, whereas combined deletion ameliorated the response. These data strongly support a role for both channels in cardiac disease and the utility of selective combined inhibition.
20 June 2014 in Circulation Research
Rationale : In cardiomyocytes from failing hearts, insufficient mitochondrial Ca 2+ accumulation secondary to cytoplasmic Na + overload decreases NAD(P)H/NAD(P) + redox potential and increases oxidative stress when workload increases. These effects are abolished by enhancing mitochondrial Ca 2+ with acute treatment with CGP-37157 (CGP), an inhibitor of the mitochondrial Na + /Ca 2+ exchanger. Objective : Our aim was to determine whether chronic CGP treatment mitigates contractile dysfunction and arrhythmias in an animal model of heart failure (HF) and sudden cardiac death (SCD). Methods and Results : Here, we describe a novel guinea pig HF/SCD model using aortic constriction combined with daily β-adrenergic receptor stimulation (ACi) and show that chronic CGP treatment (ACi plus CGP) attenuates cardiac hypertrophic remodeling, pulmonary edema, and interstitial fibrosis and prevents cardiac dysfunction and SCD. In the ACi group 4 weeks after pressure overload, fractional shortening and the rate of left ventricular pressure development decreased by 36% and 32%, respectively, compared with sham-operated controls; in contrast, cardiac function was completely preserved in the ACi plus CGP group. CGP treatment also significantly reduced the incidence of premature ventricular beats and prevented fatal episodes of ventricular fibrillation, but did not prevent QT prolongation. Without CGP treatment, mortality was 61% in the ACi group <4 weeks of aortic constriction, whereas the death rate in the ACi plus CGP group was not different from sham-operated animals. Conclusions : The findings demonstrate the critical role played by altered mitochondrial Ca 2+ dynamics in the development of HF and HF-associated SCD; moreover, they reveal a novel strategy for treating SCD and cardiac decompensation in HF.